Navigation Links
Encorium Announces Receipt of Letter from Nasdaq Regarding its 2008 Form 10-K Filing
Date:4/24/2009

lion is to be recorded in the fourth quarter of 2008.

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process. Encorium is headquartered in Wayne, Pennsylvania with its European base of operations in Espoo, Finland. The Company has a geographic footprint that includes over one billion people in North America, Western/Central/Eastern Europe, Scandinavia, and the Baltics.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions regarding future expectations. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Risks and uncertainties that could affect the Company's future operating results and financial condition generally include, without limitation: (i) th
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Encorium Appoints Shahab Fatheazam to its Board of Directors
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 2015 , ... Ticket Down is a reliable source of authentic tickets for ... , The international soccer schedule of matches played on American soil continues to ... one of the world’s greatest teams, Brazil, will travel to North America to compete ...
(Date:7/29/2015)... ... 29, 2015 , ... According to The Spirits Business on July ... responsible for stimulating and perpetuating alcohol use disorders. Humans have the same gene, which ... National academy of Sciences, and has given researchers inklings to explore Rsu1 in humans ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... changed its name in July to Kalamazoo Strength & Conditioning. , The name ... and “reflects the evolution of our training center over the past three years,” ...
(Date:7/29/2015)... FL (PRWEB) , ... July 29, 2015 , ... For ... excited to be featured in the list of the 50 fastest growing companies in ... revolves around the business community. On July 16th, a team of Vast Bridges staffers ...
(Date:7/29/2015)... ... July 29, 2015 , ... CanAm Enterprises, LLC (“CanAm”) is thrilled ... past month! I-829 approvals have been granted to investors in four different CanAm EB-5 ... Lafayette Hotel project in Philadelphia, and the Valley Forge Convention Center project in CanAm’s ...
Breaking Medicine News(10 mins):Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 3Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Vast Bridges Continues Its Swift Growth 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3
... WEDNESDAY, April 4 (HealthDay News) -- Really, really liking ... job interview, a new study suggests. That,s because ... better able to talk about and promote themselves, which ... researchers explained. In their two-part study, narcissists scored ...
... A compound found in red wine, grapes and other fruits, ... cellular processes that allow fat cells to develop, opening a ... a Purdue University study. Kee-Hong Kim, an assistant professor ... in Kim,s laboratory, reported in this week,s issue of the ...
... , WEDNESDAY, April 4 (HealthDay News) -- A new ... with a certain type of lung cancer, according to ... drug, belagenpumatucel-L (Lucanix), extended the lives of patients with ... survival rate among some patients with moderately advanced cancer ...
... 2012)When combined with other treatments, the drug cetuximabwhich works ... been shown to extend survival in certain types of ... percent of colorectal cancer patientsspecifically those who carry a ... to the drug. Researchers at Fox Chase Cancer ...
... a tendency to develop atherosclerosis the condition popularly ... LMU, in collaboration with colleagues in Wrzburg, have now ... between the two types of disorder. The link is ... plasmacytoid dendritic cells (pDCs). pDCs respond to DNA released ...
... 3 (HealthDay News) -- A new study finds that ... women to experience side effects after receiving the human papillomavirus ... serious and are similar to those associated with other vaccines. ... aged 11 to 26, within two weeks after they received ...
Cached Medicine News:Health News:Narcissists Often Ace Job Interviews, Study Finds 2Health News:Red wine, fruit compound could help block fat cell formation 2Health News:Early Study Finds Some Promise for Lung Cancer Vaccine 2Health News:Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance 2Health News:The long arm of the dendritic cell 2Health News:The long arm of the dendritic cell 3Health News:Preteens More Likely to Report HPV Vaccine Side Effects 2
(Date:7/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/zcrjfz/global ) ... Neurostimulation Devices Market 2015" report to their ... neurostimulation devices market to grow at a CAGR ... The report, Global Neurostimulation Devices Market 2015-2019, has ... with inputs from industry experts. The report covers ...
(Date:7/29/2015)... 2015 The Judicial Panel on Multidistrict Litigation ... to centralize Inferior vena cava (IVC) Filter lawsuits filed ... Medical, have already been centralized by the JPML. ... at risk for a pulmonary embolism. The filters are ... lungs. Claims against Bard and Cook involve incidents of ...
(Date:7/29/2015)... -- ViaCyte, Inc., a privately-held regenerative medicine company with the first stem ... trials, today announced the opening of a second site in its ... T olerability, and E fficacy of VC-01™ Combination P ... is the first in Canada , will be ... , Alberta.  The lead Edmonton ...
Breaking Medicine Technology:Global Neurostimulation Devices Market 2015-2019 2IVC filter litigation continues; law firm provides free information to IVC filter patients 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4
... Pharmaceuticals, Inc. (NASDAQ: IDIX ), announced today that ... Global Life Sciences Conference on September 21, 2011 at 2:00 ... The live and archived webcast of the ... the Idenix Investor Center at www.idenix.com . Please log ...
... Sept. 14, 2011 SARcode Bioscience, Inc., a ... patient has been enrolled in the company,s pivotal ... ophthalmic solution.   (Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO) ... inhibits T-cell inflammation by blocking the binding of ...
Cached Medicine Technology:First Patient Enrolled in SARcode Bioscience's Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution 2First Patient Enrolled in SARcode Bioscience's Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution 3
... G|2 Provides Microsoft Windows-based urodynamics for ... clinics where logic, efficiency and economy ... is designed with modularity and expandability ... different diagnostic tools and establish a ...
... The 6303 is an affordable ... provide full height, seat, and back ... 6303 accepts the full line of ... the perfect table for your needs; ...
For complete unobstructed imaging coverage for a wide range of urological procedures, HealthTronics urodynamics Chair/Table is the answer....
... BR2 Bilirubin STAT-Analyzer® provides a rapid, accurate ... neonates. And because it's so compact and ... virtually any laboratory. The Model BR2 is ... only instrument that measures total and direct ...
Medicine Products: